INCY - インサイト (Incyte Corporation) インサイト

 INCYのチャート


 INCYの企業情報

symbol INCY
会社名 Incyte Corporation (インサイト)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インサイト(Incyte Corporation)はバイオ医薬品会社であり、治療薬の発見・開発・商品化を主として行う。同社のポートフォリオには、前臨床開発から後期開発までの各段階の化合物、JAKAFI(ルクソリチニブ)およびICLUSIG(ポナチニブ)などの商品化された製品が含まれる。JAKAFI(ルクソリチニブ)は、中間または高リスクの骨髄線維症(MF)を有する患者の治療およびヒドロキシ尿素に不十分な応答または不耐性である真性赤血球増加症(PV)患者の治療に適応される。ICLUSIGの主な標的は、慢性骨髄性白血病およびフィラデルフィア-染色体陽性急性リンパ芽球性白血病で発現される異常なチロシンキナーゼであるB細胞受容体-ABLである。同社はまた、選択的ヤヌス関連キナーゼ1(JAK1)阻害剤のポートフォリオを有している。   インサイトは米国のバイオ医薬品企業。腫瘍学や炎症用に小分子薬剤の開発、商品化を中心に事業を展開。市販品として中間・高リスク骨髄線維症患者の治療薬、JAKAFI(ruxolitinib)を提供。また開発中の薬剤に真性多血症治療薬ruxolitinib、膵臓癌治療薬ruxolitinib、高度な悪性疾患治療薬ruxolitinibなどがある。   
本社所在地 1801 Augustine Cut-Off Wilmington DE 19803 USA
代表者氏名 Herve Hoppenot Herve Hoppenot
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 302-498-6700
設立年月日 33329
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 1208人
url www.incyte.com
nasdaq_url https://www.nasdaq.com/symbol/incy
adr_tso
EBITDA EBITDA(百万ドル) -42.51400
終値(lastsale) 64.17
時価総額(marketcap) 13641094902.33
時価総額 時価総額(百万ドル) 1442.87
売上高 売上高(百万ドル) 1729.488
企業価値(EV) 企業価値(EV)(百万ドル) 12869.058
当期純利益 当期純利益(百万ドル) -102.32100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Incyte Corporation revenues increased 27% to $903.8M. Net income totaled $11.3M vs. loss of $199.6M. Revenues reflect Product revenues net increase of 26% to $700M Product royalty revenues increase of 62% to $103.7M Milestone revenues increase of 11% to $100M. Net Income reflects Other Research and development decrease of 18% to $445M (expense).

 INCYのテクニカル分析


 INCYのニュース

   Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021  2021/03/11 13:00:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR21--Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021.
   Genentech gains clinical development exec by appointing Lilli Petruzzelli; Paul Sekhri caps eventful week, naming Sapna Srivastava CFO of eGenesis  2021/03/05 14:53:10 Endpoints News
→ A spokesperson for Genentech tells Endpoints News that Lilli Petruzzelli has forged a new path this week as SVP, early clinical development at Genentech’s Research and Early Development organization (gRED). Petruzzelli just spent two years as Incyte’s group VP, early clinical development, and prior to Incyte, she was global
   Samenvatting: Incyte kondigt de validatie door het Europees Geneesmiddelenbureau aan van zijn aanvraag voor een vergunning voor het in de handel brengen van Retifanlimab als behandeling voor patiënten met plaveiselcelanaal carcinoom (SCAC)  2021/02/26 14:55:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) heeft vandaag de validatie aangekondigd van de Marketing Authorization Application (MAA) van het bedrijf voor retifanlimab, een intraveneuze PD-1-remmer, als een mogelijke behandeling voor volwassen patiënten met lokaal gevorderde of gemetastaseerd plaveiselcelanaalcarcinoom (SCAC) bij wie progressie is opgetreden tijdens of die platina-gebaseerde chemotherapie niet verdraagt. De validatie van de MAA door het Europees Geneesmiddelenbureau
   FXNEWS24 |Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates | UK Forex Reviews  2021/02/24 21:53:41 FXNews24
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Incyte (NASDAQ:INCY) Releases Quarterly Earnings Results  2021/02/10 17:43:53 Transcript Daily
Incyte (NASDAQ:INCY) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.30, Briefing.com reports. The business had revenue of $788.50 million during the quarter, compared to the consensus estimate of $654.08 million. Incyte had a negative net margin of […]
   Genentech gains clinical development exec by appointing Lilli Petruzzelli; Paul Sekhri caps eventful week, naming Sapna Srivastava CFO of eGenesis  2021/03/05 14:53:10 Endpoints News
→ A spokesperson for Genentech tells Endpoints News that Lilli Petruzzelli has forged a new path this week as SVP, early clinical development at Genentech’s Research and Early Development organization (gRED). Petruzzelli just spent two years as Incyte’s group VP, early clinical development, and prior to Incyte, she was global
   Samenvatting: Incyte kondigt de validatie door het Europees Geneesmiddelenbureau aan van zijn aanvraag voor een vergunning voor het in de handel brengen van Retifanlimab als behandeling voor patiënten met plaveiselcelanaal carcinoom (SCAC)  2021/02/26 14:55:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) heeft vandaag de validatie aangekondigd van de Marketing Authorization Application (MAA) van het bedrijf voor retifanlimab, een intraveneuze PD-1-remmer, als een mogelijke behandeling voor volwassen patiënten met lokaal gevorderde of gemetastaseerd plaveiselcelanaalcarcinoom (SCAC) bij wie progressie is opgetreden tijdens of die platina-gebaseerde chemotherapie niet verdraagt. De validatie van de MAA door het Europees Geneesmiddelenbureau
   FXNEWS24 |Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates | UK Forex Reviews  2021/02/24 21:53:41 FXNews24
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Incyte (NASDAQ:INCY) Releases Quarterly Earnings Results  2021/02/10 17:43:53 Transcript Daily
Incyte (NASDAQ:INCY) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.30, Briefing.com reports. The business had revenue of $788.50 million during the quarter, compared to the consensus estimate of $654.08 million. Incyte had a negative net margin of […]
   Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs  2021/02/09 12:00:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs
   Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab  2021/01/12 21:00:00 Benzinga
MONTREAL and PLANEGG/ MUNICH, Germany , Jan. 12, 2021 /CNW/ - Incyte (NASDAQ: INCY ) and MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ: MOR ) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT). "With the acceptance of the NDS by Health Canada, review of the data can begin, an important step on the path to making tafasitamab available in Canada for use in combination with lenalidomide in eligible patients with relapsed or refractory DLBCL," said Josée Brisebois, Ph.D., Head of Medical Affairs, Incyte Biosciences Canada. "We intend to work closely with Health Canada as we seek to bring this innovative targeted therapeutic option to the clinical community and to appropriate patients for whom few treatment options exist." "This important milestone moves tafasitamab in combination with lenalidomide into the regulatory review process in Canada , with the potential to significantly advance patient care in the treatment of relapsed or refractory DLBCL," said Nuwan Kurukulasuriya , Ph.D., Senior Vice President Global Medical Affairs, MorphoSys.
   Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804  2020/12/30 12:30:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
   Covid-19 roundup: Incyte, Novartis report PhIII flop for repurposed Jakafi; US to distribute first vaccines Monday  2020/12/14 11:55:31 Endpoints News
Is it time to cross off another theory for treating cytokine storms associated with Covid-19? Incyte's Jakafi — or Jakavi as its partner Novartis markets the drug outside of the US — failed to make any difference for patients 12 years and older when added to standard-of-care in a Phase
   Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine  2020/12/11 19:01:00 PR Newswire
INDIANAPOLIS, Dec. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of…
   Incyte to Present at Upcoming Investor Conference  2020/12/09 13:00:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 39th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, d

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インサイト INCY Incyte Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)